Supplementary Material 1-PROSPERO

PROSPERO
International prospective register of systematic reviews

NHS
National Institute for Health Research

UNIVERSITY of York
Centre for Reviews and Dissemination

Systematic review

A list of fields that can be edited in an update can be found here

1. * Review title.

Give the title of the review in English

Efficacy of Dachaihu Decoction in Patients with hyperlipemia: A Systematic Review and Meta-Analysis

2. Original language title.

For reviews in languages other than English, give the title in the original language. This will be displayed with the English language title.

3. * Anticipated or actual start date.

Give the date the systematic review started or is expected to start.

01/07/2024

4. * Anticipated completion date.

Give the date by which the review is expected to be completed.

30/09/2024

5. * Stage of review at time of this submission.

This field uses answers to initial screening questions. It cannot be edited until after registration.

Tick the boxes to show which review tasks have been started and which have been completed.

Update this field each time any amendments are made to a published record.

The review has not yet started: No

Review stage	Started	Completed
Preliminary searches	Yes	No
Piloting of the study selection process	Yes	No
Formal screening of search results against eligibility criteria	No	No
Data extraction	No	No
Risk of bias (quality) assessment	No	No
Data analysis	No	No

Provide any other relevant information about the stage of the review here.

6. * Named contact.

The named contact is the guarantor for the accuracy of the information in the register record. This may be any member of the review team.

Wenyu Bu

Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence:

Ms Bu

7. * Named contact email.

Give the electronic email address of the named contact.

1264450663@qq.com

8. Named contact address

Give the full institutional/organisational postal address for the named contact.

Nanjing University Of Chinese Medicine

9. Named contact phone number.

Give the telephone number for the named contact, including international dialling code.

18352871968

10. * Organisational affiliation of the review.

Full title of the organisational affiliations for this review and website address if available. This field may be completed as 'None' if the review is not affiliated to any organisation.

Nanjing University Of Chinese Medicine

Organisation web address:

11. * Review team members and their organisational affiliations.

Give the personal details and the organisational affiliations of each member of the review team. Affiliation refers to groups or organisations to which review team members belong. **NOTE: email and country now MUST be entered for each person, unless you are amending a published record. PLEASE USE AN INSTITUTIONAL EMAIL ADDRESS IF POSSIBLE.**

Ms Wenyu Bu. Nanjing University Of Chinese Medicine
Mr Yang Sheng. Nanjing University Of Chinese Medicine
Ms Qiuyu Yu. Nanjing University Of Chinese Medicine
Miss Zixun Zhuang. Nanjing University Of Chinese Medicine

12. * Funding sources/sponsors.

Details of the individuals, organizations, groups, companies or other legal entities who have funded or sponsored the review.

None

Grant number(s)

State the funder, grant or award number and the date of award

13. * Conflicts of interest.

List actual or perceived conflicts of interest (financial or academic).

None

14. Collaborators.

Give the name and affiliation of any individuals or organisations who are working on the review but who are not listed as review team members. **NOTE: email and country must be completed for each person, unless you are amending a published record.**

15. * Review question.

State the review question(s) clearly and precisely. It may be appropriate to break very broad questions down into a series of related more specific questions. Questions may be framed or refined using PI(E)COS or similar where relevant.

We propose to conduct a systematic review aiming to summarize the evidence for the effectiveness and safety of Dachaihu Decoction for patients with hyperlipemia.

16. * Searches.

State the sources that will be searched (e.g. Medline). Give the search dates, and any restrictions (e.g. language or publication date). Do NOT enter the full search strategy (it may be provided as a link or attachment below.)

We will search the following electronic databases, regardless of the publicationg status: The Cochrane Library ofControlled Trials (CENTRAL), PubMed, EMBASE, Chinese Biomedical Literature Database(CMB), China NationalKnowledge Infrastructure (CNKI), Chinese Scientific Journal Database(VIP database), Wan-Fang database. We onlyincluded English and Chinese language.The following search terms will be used: hyperlipemia combined with Dachaihu Decoction. The search words used in Chinese databases have the same meaning as theversion.

17. URL to search strategy.

Upload a file with your search strategy, or an example of a search strategy for a specific database, (including the keywords) in pdf or word format. In doing so you are consenting to the file being made publicly accessible. Or provide a URL or link to the strategy. Do NOT provide links to your search **results**.

Alternatively, upload your search strategy to CRD in pdf format. Please note that by doing so you are consenting to the file being made publicly accessible.

Do not make this file publicly available until the review is complete

18. * Condition or domain being studied.

Give a short description of the disease, condition or healthcare domain being studied in your systematic review.

Hyperlipemia is a common metabolic disorder characterized by elevated blood levels of total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), and decreased levels of high-density lipoprotein (HDL-C). hyperlipemia interacts with other cardiovascular risk factors and can easily lead to a variety of heart and vascular diseases such as atherosclerosis, coronary heart disease, and cerebral infarction, thus increasing the incidence of cardiovascular and cerebrovascular diseases.

19. * Participants/population.

Specify the participants or populations being studied in the review. The preferred format includes details of both inclusion and exclusion criteria.

Patients with a clinical diagnosis of Hyperlipemia will be included in our study (age =18 years old), regardless of gender, race, education and economic status.

20. * Intervention(s), exposure(s).

Give full and clear descriptions or definitions of the interventions or the exposures to be reviewed. The preferred format includes details of both inclusion and exclusion criteria.

Dachaihu Decoction (DCHD) alone or DCHD combined with Western medicine or DCHD combined with complementary andalternative medical therapies (including drugs, acupuncture, exercise, and diet change) was used. There was no limitto the dosage and course of DCHD.

21. * Comparator(s)/control.

Where relevant, give details of the alternatives against which the intervention/exposure will be compared (e.g. another intervention or a non-exposed control group). The preferred format includes details of both inclusion and exclusion criteria.

The control group included blank control, placebo control, Western medicine, and complementary and alternativemedicine therapy groups.

22. * Types of study to be included.

Give details of the study designs (e.g. RCT) that are eligible for inclusion in the review. The preferred format includes both inclusion and exclusion criteria. If there are no restrictions on the types of study, this should be stated.

We will include randomized controlled trials (RCTs) based on the treatment of hyperlipemia with Dachaihu decoction, regardless of publication status and language.

23. Context.

Give summary details of the setting or other relevant characteristics, which help define the inclusion or exclusion criteria.

24. * Main outcome(s).

Give the pre-specified main (most important) outcomes of the review, including details of how the outcome is defined and measured and when these measurement are made, if these are part of the review inclusion criteria.

Lipid Metabolism Index: includes, but is not limited to, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), as well as the number of people who have returned to a normal level of lipids (also referred to as normalized lipid levels).

Measures of effect

Please specify the effect measure(s) for you main outcome(s) e.g. relative risks, odds ratios, risk difference, and/or 'number needed to treat.

25. * Additional outcome(s).

List the pre-specified additional outcomes of the review, with a similar level of detail to that required for main outcomes. Where there are no additional outcomes please state 'None' or 'Not applicable' as appropriate to the review

Body Mass Index indicators

Blood Pressure

Blood Sugar

Adverse effects

Measures of effect

Please specify the effect measure(s) for you additional outcome(s) e.g. relative risks, odds ratios, risk difference, and/or 'number needed to treat.

26. * Data extraction (selection and coding).

Describe how studies will be selected for inclusion. State what data will be extracted or obtained. State how this will be done and recorded.

EndNote X9 software will be used to manage electronic and manual search results and to build the database. Two researchers (BWY and SY) will independently screen the literature based on inclusion and exclusion criteria. Any objections will be discussed and finalized in consultation with the 3rd researcher, YQY. The two researchers will independently extract data from the included studies according to a pre-designed data extraction form. If some additional data are required or not needed in the experiment, we will contact the authors by email for further information. The extracted study data included, among others, the name of the first author, year of publication, source of funding, location of the study, diagnostic criteria, inclusion criteria, exclusion criteria, study population, sample size, proportion of gender distribution, mean age, duration of disease, duration of treatment, interventions, outcome metrics (end-of-treatment and followup), comorbidities, and adverse events, and cross-checks were performed.

27. * Risk of bias (quality) assessment.

State which characteristics of the studies will be assessed and/or any formal risk of bias/quality assessment tools that will be used.

Two independent reviewers (BWY and SY) assessed whether the risk of bias for each criterion was considered lowrisk, high risk or unclear risk, using the risk of bias approach for Cochrane reviews. Disagreements were resolved bydiscussion or the third reviewer (YQY). We used the following six separate criteria:

(1)Adequate sequence generation;

(2)Allocation concealment;

(3)Blinding (performance bias and detection bias);

(4)Incomplete outcome data;

(5)Selective reporting;

(6)Other bias.

Particularly, we will use the Grades Profile as the Grading of Recommendation, Assessment, Development, andEvaluation (GRADE) system to grading the quality of the evidence.

28. * Strategy for data synthesis.

Describe the methods you plan to use to synthesise data. This **must not be generic text** but should be **specific to your review** and describe how the proposed approach will be applied to your data. If meta-analysis is planned, describe the models to be used, methods to explore statistical heterogeneity, and software package to be used.

We will use the Review Manager software V.5.3 to carry out statistical analysis. Mean difference (MD) orstandardized means difference (SMD) was used for continuous data. Risk ratio (RR) or risk difference (RD) was usedfor the analysis of dichotomous data. In the case of homogeneous data, the fixed-effects model was used. In thecase of heterogeneity, we used the random-effects model.

29. * Analysis of subgroups or subsets.

State any planned investigation of 'subgroups'. Be clear and specific about which type of study or participant will be included in each group or covariate investigated. State the planned analytic approach.

If one of the outcome parameters demonstrates statistically significant differences between intervention groups, wewill plan to use subgroup analyses. Planned subgroup analyses will be performed in: disease status at baseline, different intervention and so on.

30. * Type and method of review.

Select the type of review, review method and health area from the lists below.

Type of review

Cost effectiveness
No

Diagnostic
No

Epidemiologic
No

Individual patient data (IPD) meta-analysis
No

Intervention
Yes

Living systematic review
No

Meta-analysis
Yes

Methodology
No

Narrative synthesis

No

Network meta-analysis
No

Pre-clinical
No

Prevention
No

Prognostic
No

Prospective meta-analysis (PMA)
No

Review of reviews
No

Service delivery
No

Synthesis of qualitative studies
No

Systematic review
Yes

Other
No

Health area of the review

Alcohol/substance misuse/abuse
No

Blood and immune system
No

Cancer
No

Cardiovascular
Yes

Care of the elderly
No

Child health
No

Complementary therapies

No

COVID-19
No

Crime and justice
No

Dental
No

Digestive system
No

Ear, nose and throat
No

Education
No

Endocrine and metabolic disorders
No

Eye disorders
No

General interest
No

Genetics
No

Health inequalities/health equity
No

Infections and infestations
No

International development
No

Mental health and behavioural conditions
No

Musculoskeletal
No

Neurological
No

Nursing
No

Obstetrics and gynaecology

No

Oral health
No

Palliative care
No

Perioperative care
No

Physiotherapy
No

Pregnancy and childbirth
No

Public health (including social determinants of health)
No

Rehabilitation
No

Respiratory disorders
No

Service delivery
No

Skin disorders
No

Social care
No

Surgery
No

Tropical Medicine
No

Urological
No

Wounds, injuries and accidents
No

Violence and abuse
No

31. Language.

Select each language individually to add it to the list below, use the bin icon to remove any added in error.

English

There is an English language summary.

32. * Country.

Select the country in which the review is being carried out. For multi-national collaborations select all the countries involved.

China

33. Other registration details.

Name any other organisation where the systematic review title or protocol is registered (e.g. Campbell, or The Joanna Briggs Institute) together with any unique identification number assigned by them. If extracted data will be stored and made available through a repository such as the Systematic Review Data Repository (SRDR), details and a link should be included here. If none, leave blank.

34. Reference and/or URL for published protocol.

If the protocol for this review is published provide details (authors, title and journal details, preferably in Vancouver format)

Add web link to the published protocol.

Or, upload your published protocol here in pdf format. Note that the upload will be publicly accessible.

No I do not make this file publicly available until the review is complete

Please note that the information required in the PROSPERO registration form must be completed in full even if access to a protocol is given.

35. Dissemination plans.

Do you intend to publish the review on completion?

Yes

Give brief details of plans for communicating review findings.?

36. Keywords.

Give words or phrases that best describe the review. Separate keywords with a semicolon or new line. Keywords help PROSPERO users find your review (keywords do not appear in the public record but are included in searches). Be as specific and precise as possible. Avoid acronyms and abbreviations unless these are in wide use.

37. Details of any existing review of the same topic by the same authors.

If you are registering an update of an existing review give details of the earlier versions and include a full bibliographic reference, if available.

38. * Current review status.

Update review status when the review is completed and when it is published.New registrations must be ongoing so this field is not editable for initial submission.

Please provide anticipated publication date

Review_Ongoing

39. Any additional information.

Provide any other information relevant to the registration of this review.

40. Details of final report/publication(s) or preprints if available.

Leave empty until publication details are available OR you have a link to a preprint (NOTE: this field is not editable for initial submission). List authors, title and journal details preferably in Vancouver format.

Give the link to the published review or preprint.